Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazbentetol - Spinogenix

Drug Profile

Tazbentetol - Spinogenix

Alternative Names: SPG-302; Tazbentetol-Spinogenix

Latest Information Update: 25 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spinogenix
  • Class Antidementias; Antiglaucomas; Antineoplastics; Antipsychotics; Benzene derivatives; Benzothiazoles; Ethylene glycols; Neuroprotectants; Small molecules
  • Mechanism of Action Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Schizophrenia
  • Preclinical Glaucoma

Most Recent Events

  • 08 Dec 2025 Spinogenix completes phase II clinical trials in Alzheimer's disease in Australia (PO) (NCT06427668)
  • 08 Dec 2025 Updated efficacy, adverse events and pharmacodynamics data from a phase II clinical trial in Alzheimer's disease
  • 01 Dec 2025 The International Nonproprietary Names (INN) Expert Committee of the World Health Organization approves 'tazbentetol' as the non-proprietary name of SPG

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top